New medicine to treat infections in adults
Vabomere, a combination of an antibiotic and new beta-lactamase inhibitor, addresses bacterial resistance
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Vabomere (meropenem trihydrate/vaborbactam), a new treatment option against the following infections in adults:
- Complicated urinary tract infection, including pyelonephritis, a sudden and severe infection causing the kidneys to swell and which may permanently damage them;
- Complicated intra-abdominal infection;
- Hospital-acquired pneumonia, including ventilator associated pneumonia;
- Bacteria in the blood associated with any of the infections listed above;
- Infections due to aerobic Gram-negative organisms in adults with limited treatment options.
The lack of availability of medicines to treat patients with infections caused by resistant bacteria has become a major problem in recent years. It is estimated that at least 25,000 patients in the European Union (EU) die each year from infections due to bacteria that are resistant to many medicines.
Vabomere is a fixed combination of vaborbactam, a new beta-lactamase inhibitor and meropenem, a broad-spectrum antibiotic belonging to the class of carbapenems that is already approved for use in the EU. It is a powder for concentrate for solution for infusion (drip into a vein).
Resistance to carbapenems has been increasing lately, in particular in Gram-negative bacteria, and is of major concern. Beta-lactamases are enzymes involved in bacterial resistance to these antibiotics. By inhibiting the action of beta-lactamases, vaborbactam protects meropenem from being inactivated and restores its activity against many, but not all, carbapenem-resistant pathogens.
In the clinical development program, the exposure to vaborbactam at the recommended dose was shown to be sufficient to protect the activity of meropenem against carbapenem-resistant Enterobacteriaceae. The CHMP also agreed that the studies did not indicate any major concerns regarding the safety profile of meropenem-vaborbactam.
EMA contributes to the European and global effort to tackle antimicrobial resistance. A major area of activity is to create an environment that stimulates and facilitates the development of new antimicrobials. The Agency’s activities also include the monitoring and analysis of data on antimicrobials to guide policy and research, as well as the promotion of their responsible use.
The opinion adopted by the CHMP is an intermediary step on Vabomere’s path to patient access. The opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorisation. Once the marketing authorisations has been granted, decisions about price and reimbursement will take place at the level of each Member State, taking into account the potential role/use of this medicine in the context of the national health system of that country.
- The applicant for is Rempex London Ltd.
|New medicine to treat infections in adults||(English only)||21/09/2018|
Latest News from
Statement by Commissioner Virginijus Sinkevičius on a new approach for a sustainable blue economy in the EU18/05/2021 14:38:00
Statement given yesterday by Commissioner Virginijus Sinkevičius on a new approach for a sustainable blue economy in the EU.
European Green Deal: Developing a sustainable blue economy in the European Union18/05/2021 13:25:00
The European Commission yesterday proposed a new approach for a sustainable blue economy in the EU for the industries and sectors related to oceans, seas and coasts.
EU Blue Card: Commission welcomes political agreement on new rules for highly skilled migrant workers18/05/2021 12:33:00
The Commission welcomes the agreement reached today by the European Parliament and the Council on new rules for the entry and residence of highly skilled workers from outside the EU under the revised Blue Card Directive.
Nagorno Karabakh conflict: EU allocates additional €10 million to support those affected18/05/2021 09:25:00
As part of its efforts to strengthen resilience and peace building in the South Caucasus, the Commission is delivering on its pledge to contribute an additional €10 million in humanitarian aid, including some very early recovery to help civilians affected by the recent conflict in and around Nagorno Karabakh.
Recovery and Resilience Facility: Croatia and Lithuania submit official recovery and resilience plans17/05/2021 15:25:00
The Commission has received official recovery and resilience plans from Croatia and Lithuania.
Speech by President von der Leyen on the occasion of the Christchurch Call Second Anniversary Summit17/05/2021 13:25:00
Speech given recently (14 May 2021) by President von der Leyen on the occasion of the Christchurch Call Second Anniversary Summit.
International Day Against Homophobia, Transphobia and Biphobia, 17 May 2021: Declaration by the High Representative on behalf of the EU17/05/2021 12:38:00
Everyone is born free and equal in dignity and rights. On the International Day against Homophobia, Transphobia and Biphobia (IDAHOT), the European Union reaffirms its strong commitment to respect, protect and promote the full and equal enjoyment of human rights of lesbian, gay, bisexual, transgender and intersex (LGBTI) persons.
Spring 2021 Economic Forecast: Rolling up sleeves14/05/2021 13:25:00
The Spring 2021 Economic Forecast projects that the EU economy will expand by 4.2% in 2021 and by 4.4% in 2022.
Coronavirus variants: Commission calls for limiting essential travel from India14/05/2021 09:25:00
The Commission calls on EU Member States to take coordinated action to further restrict travel from India on a temporary basis, with a view to limiting the spread of the B.1.617.2 variant first detected in India.
Statement by Executive Vice-President Margrethe Vestager following today's Court judgments on the Amazon and Engie tax State aid cases in Luxembourg13/05/2021 15:25:00
Statement given yesterday by Executive Vice-President Margrethe Vestager following the Court judgments on the Amazon and Engie tax State aid cases in Luxembourg.